Treatment of Primary CNS Lymphoma With High-Dose Methotrexate in Immunocompetent Pediatric Patients

被引:15
|
作者
Shah, Amish C. [1 ]
Kelly, David R. [2 ]
Nabors, L. Burt [3 ]
Oakes, W. Jerry [4 ]
Hilliard, Lee M. [5 ]
Reddy, Alyssa T. [3 ,4 ,5 ]
机构
[1] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA
[2] Univ Alabama Birmingham, Dept Pathol, Sch Med, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Dept Neurol, Sch Med, Birmingham, AL 35294 USA
[4] Univ Alabama Birmingham, Sch Med, Dept Surg, Birmingham, AL 35294 USA
[5] Univ Alabama Birmingham, Sch Med, Dept Pediat, Birmingham, AL USA
关键词
anaplastic large cell lymphoma; diffuse large B-cell lymphoma; methotrexate; primary central nervous system lymphoma; CENTRAL-NERVOUS-SYSTEM; LONG-TERM SURVIVAL; THERAPEUTIC MANAGEMENT; EPIDEMIOLOGY;
D O I
10.1002/pbc.22752
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We report two cases of primary CNS lymphoma (PCNSL) treated with high-close methotrexate. Though standard adult treatment of PCNSL incorporates whole-brain radiotherapy, the literature suggests it may be possible to delay or avoid radiotherapy and the associated increased risk of neurologic sequelae in pediatric patients. Studies in adults indicate methotrexate therapy can be effective against PCNSL and has advantages over the current standard of treatment. Both patients have no evidence of disease 9 and 7 years after treatment, suggesting high-close methotrexate may lead to disease control in pediatric patients with PCNSL while avoiding the effects of radiotherapy. Pediatr Blood Cancer. 2010;55:1227-1230. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:1227 / 1230
页数:4
相关论文
共 50 条
  • [1] Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma
    Momota, Hiroyuki
    Narita, Yoshitaka
    Maeshima, Akiko M.
    Miyakita, Yasuji
    Shinomiya, Aya
    Maruyama, Takashi
    Muragaki, Yoshihiro
    Shibui, Soichiro
    JOURNAL OF NEURO-ONCOLOGY, 2010, 98 (03) : 341 - 348
  • [2] High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
    Ferreri, Andres J. M.
    Reni, Michele
    Foppoli, Marco
    Martelli, Maurizio
    Pangalis, Gerasimus A.
    Frezzato, Maurizio
    Cabras, Maria Giuseppina
    Fabbri, Alberto
    Corazzelli, Gaetano
    Ilariucci, Fiorella
    Rossi, Giuseppe
    Soffietti, Riccardo
    Stelitano, Caterina
    Vallisa, Daniele
    Zaja, Francesco
    Zoppegno, Lucia
    Aondio, Gian Marco
    Avvisati, Giuseppe
    Balzarotti, Monica
    Brandes, Alba A.
    Fajardo, Jose
    Gomez, Henry
    Guarini, Attilio
    Pinotti, Graziella
    Rigacci, Luigi
    Uhlmann, Catrina
    Picozzi, Piero
    Vezzulli, Paolo
    Ponzoni, Maurilio
    Zucca, Emanuele
    Caligaris-Cappio, Federico
    Cavalli, Franco
    LANCET, 2009, 374 (9700) : 1512 - 1520
  • [3] High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors
    DeAtkine, Andrew B.
    Abdelrashid, Moaaz
    Tucker, Zach
    Mehta, Amitkumar
    Markert, James M.
    Kim, Jinsuh
    Fiveash, John B.
    Oster, Robert A.
    Lobbous, Mina
    Nabors, L. Burt
    JOURNAL OF NEURO-ONCOLOGY, 2022, 158 (01) : 33 - 40
  • [4] Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma
    Hiroyuki Momota
    Yoshitaka Narita
    Akiko M. Maeshima
    Yasuji Miyakita
    Aya Shinomiya
    Takashi Maruyama
    Yoshihiro Muragaki
    Soichiro Shibui
    Journal of Neuro-Oncology, 2010, 98 : 341 - 348
  • [5] Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma
    Ponzoni, M.
    Issa, S.
    Batchelor, T. T.
    Rubenstein, J. L.
    ANNALS OF ONCOLOGY, 2014, 25 (02) : 316 - 322
  • [6] High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors
    Andrew B. DeAtkine
    Moaaz Abdelrashid
    Zach Tucker
    Amitkumar Mehta
    James M. Markert
    Jinsuh Kim
    John B. Fiveash
    Robert A. Oster
    Mina Lobbous
    L. Burt Nabors
    Journal of Neuro-Oncology, 2022, 158 : 33 - 40
  • [7] Primary CNS Lymphoma in Immunocompetent Patients
    del Rio, Monica Sierra
    Rousseau, Audrey
    Soussain, Carole
    Ricard, Damien
    Hoang-Xuan, Khe
    ONCOLOGIST, 2009, 14 (05) : 526 - 539
  • [8] Crystalline Nephropathy With High-Dose Methotrexate in a Patient With Primary CNS Lymphoma: A Case Report
    Sami, Faria Latif
    Hammo, Hasan
    Athavale, Ambarish
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
  • [9] Efficacy and safety of first-line high-dose cytarabine in patients with primary CNS lymphoma ineligible for high-dose methotrexate: A case series
    Zeremski, Vanja
    Haage, Tobias Ronny
    Mougiakakos, Dimitrios
    NEURO-ONCOLOGY PRACTICE, 2024, : 168 - 172
  • [10] Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma
    Mei, Shenghui
    Li, Xingang
    Jiang, Xueyun
    Yu, Kefu
    Lin, Song
    Zhao, Zhigang
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 107 (05) : 1454 - 1460